4-iodo-3-(methoxymethoxy)benzyl alcohol | 81245-33-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-iodo-3-(methoxymethoxy)benzyl alcohol
• 英文别名: [4-Iodo-3-(methoxymethoxy)phenyl]methanol
• CAS: 81245-33-2
• 化学式: C₉H₁₁IO₃
• 分子量: 294.089
• InChiKey: ZOGPXKXUPPVQPU-UHFFFAOYSA-N

物化性质

• 沸点：
  99-101 °C(Press: 0.01 Torr)
• 密度：
  1.707±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 3-(methoxymethoxy)benzoate 在 lithium aluminium tetrahydride 、 四甲基乙二胺 、 叔丁基锂 作用下， 以 乙醚 为溶剂， 生成 4-iodo-3-(methoxymethoxy)benzyl alcohol
  参考文献：
  名称：

  Regioselective metallations of (methoxymethoxy)arenes

  摘要：

  DOI：

  10.1016/s0040-4020(01)91921-0

文献信息

• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• TISSUE FACTOR PRODUCTION INHIBITOR
  申请人：Sankyo Company, Limited

  公开号：EP1764075A1

  公开（公告）日：2007-03-21

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种具有抑制组织因子生成活性的药物，其活性成分包括一种 LXR 配体；用于治疗和/或预防血管成形术、动脉内膜切除术、经皮腔内冠状动脉成形术（PTCA）或支架植入术后的血管再狭窄，或治疗和/或预防血液凝固疾病、血小板聚集诱发的疾病（包括稳定型或不稳定型心绞痛）的药物、心脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病、溶栓后的再血栓形成、脑缺血发作、脑梗塞、中风、缺血性痴呆、外周动脉疾病、使用主动脉-冠状动脉搭桥过程中的血栓栓塞形成疾病、肾小球硬化、肾栓塞、肿瘤或癌症转移，其活性成分包括 LXR 配体。
• Regioselective metalation reactions of some substituted (methoxymethoxy)arenes
  作者：Mark R. Winkle、Robert C. Ronald

  DOI：10.1021/jo00132a022

  日期：1982.5
• WINKLE, M. R.;RONALD, R. C., J. ORG. CHEM., 1982, 47, N 11, 2101-2108
  作者：WINKLE, M. R.、RONALD, R. C.

  DOI：——

  日期：——
• RONALD, R. C.;WINKLE, M. R., TETRAHEDRON, 1983, 39, N 12, 2031-2042
  作者：RONALD, R. C.、WINKLE, M. R.

  DOI：——

  日期：——